Visit our Location
11860 Vista Del Sol Dr Suite 105,
El Paso, TX 79936
Give us a Call
+1 (915) 412-6680
Send us a Message
[email protected]
Opening Hours
Mon-Thu: 7 AM - 7 PM
Fri - Sun: Closed

Tag: progesterone

ChiroMedBlogprogesterone

Hormonal Health: What You Need to Know About Sarcopenia


Explore the connection between sarcopenia and hormonal health for better overall vitality and strength in your daily life.

Abstract

Welcome to this in-depth exploration of hormonal health, cellular aging, and the management of chronic diseases like cancer. As a clinician with a diverse background in chiropractic, nursing, and functional medicine, my goal is to bridge the gap between conventional treatments and integrative therapies. In this educational post, I will guide you through the intricate world of hormone replacement therapy (HRT), discussing its profound impact on the body and brain, particularly in the context of aging and menopause. We will delve into the critical roles of hormones like estrogen and progesterone, examining how their balance affects everything from bone density and cognitive function to cancer risk. I will present the latest findings from leading researchers, highlighting the nuanced differences between synthetic and bioidentical hormones and why this distinction matters for long-term health. Furthermore, we will explore the concept of metabolic flexibility and the physiological underpinnings of conditions like insulin resistance, explaining how diet and lifestyle interventions can powerfully influence cellular health. Finally, I will explain how integrative chiropractic care serves as a foundational element in this holistic model, supporting the nervous system and enhancing the body’s innate ability to heal, thereby creating a comprehensive and personalized path to wellness.

The Hormone Conundrum: Understanding the Brain-Body Connection in Aging

In my years of clinical practice, one of the most common and often misunderstood topics I encounter is hormonal change, especially during menopause. Many patients come to me with a sense of inevitability about the associated symptoms—hot flashes, brain fog, sleep disturbances, and a general decline in vitality. A prevalent belief is that these are simply unavoidable consequences of aging. However, modern, evidence-based research tells us a different story.

When a woman’s ovaries cease producing estrogen during menopause, it’s not just a reproductive event; it’s a systemic one that profoundly affects the entire body, most notably the brain. Think of estrogen as a master regulator for cerebral function. It is crucial for neurotransmitter synthesis, glucose utilization, and neuronal protection.

For example, when estrogen levels plummet, the brain’s ability to use glucose—its primary fuel source—is significantly impaired. This metabolic shift can lead to the classic “brain fog,” memory lapses, and even an increased risk for neurodegenerative diseases later in life. This isn’t a temporary state. As soon as a woman stops producing her own ovarian estrogen or discontinues hormone replacement therapy, these neurological changes can manifest. My clinical observations align with this; I’ve seen patients who stop HRT after years of use and report an almost immediate return of cognitive and vasomotor symptoms (like hot flashes), regardless of how long they were on the therapy. The brain doesn’t just “get used to it” and pick up the slack. The hormonal support is either there or it isn’t.

This brings us to a critical point: the notion of “getting off” hormones as a goal. While this might seem prudent based on older, often misinterpreted studies, the physiological reality is that for many, these hormones are replacing a vital substance the body no longer makes. It’s akin to a person with hypothyroidism taking thyroid medication. We don’t advise them to “get off” their medication after a few years; we understand it is replacing a crucial hormone for life. The same logic should be applied to HRT, with careful consideration.

Re-evaluating Hormone Replacement Therapy (HRT): Synthetic vs. Bioidentical

The conversation around HRT is often clouded by fear, largely stemming from the initial reports of the Women’s Health Initiative (WHI) study. This landmark study raised alarms about increased risks of breast cancer and cardiovascular events. However, a deeper dive into the methodology reveals critical flaws that limit its applicability to many women today.

  • The Problem with Progestins: The WHI primarily used a combination of conjugated equine estrogens (derived from horse urine) and a synthetic progestin called medroxyprogesterone acetate (MPA). Research, including a pivotal study by Formby and Wiley (2012), has since demonstrated that synthetic progestins such as MPA can have a proliferative effect on breast tissue, thereby encouraging cancer cell growth.
  • The Power of Bioidentical Progesterone: In stark contrast, bioidentical progesterone—which is molecularly identical to the progesterone our bodies produce—exhibits a different, protective action. It promotes apoptosis, or programmed cell death, in breast cancer cells. This means it helps the body eliminate abnormal cells rather than allowing them to multiply.
  • The Estrogen-Progesterone Dance: Estrogen, when unopposed, can stimulate cell growth (the mitogenic effect). Progesterone’s role is to balance this by signaling for cell differentiation and controlled cell death. When you use a synthetic progestin that fails to provide this apoptotic signal, you lose the protective balance, creating an environment where estrogen’s proliferative effects can dominate. This is a crucial distinction that is often lost in mainstream discussions.

In my practice, I emphasize the importance of using bioidentical hormones. The goal is to replicate the body’s natural hormonal milieu as closely as possible, providing the benefits of estrogen while ensuring the protective counterbalance of progesterone. We don’t just give hormones; we test, monitor, and tailor the dosage to achieve a physiological balance that supports long-term health, not just symptom relief.

The Oncologist’s Perspective: Bridging the Gap with Evidence

One of the greatest challenges my patients face is navigating conversations about HRT with their oncologists, particularly after a cancer diagnosis like breast cancer. The conventional oncology perspective is often one of extreme caution, recommending the avoidance of all hormones. While this stems from a desire to “do no harm,” it is often based on an outdated and incomplete understanding of hormonal physiology.

My approach is to empower my patients with data. We don’t just talk; we test. We use advanced functional testing, such as the DUTCH (Dried Urine Test for Comprehensive Hormones), to map a patient’s hormone metabolites. This allows us to see not just the level of estrogen but how the body is processing it.

  • Protective vs. Risky Metabolites: Estrogen is broken down into several metabolites. Some, like 2-hydroxyestrone (2-OHE1), are considered protective. Others, like 4-hydroxyestrone (4-OHE1) and 16-alpha-hydroxyestrone (16α-OHE1), can have genotoxic effects, meaning they can damage DNA and increase cancer risk.
  • Empowering the Patient-Doctor Dialogue: By presenting an oncologist with a report indicating that a patient’s metabolic pathways favor the protective 2-OHE1 pathway, we can shift the conversation. We can demonstrate, with objective data, that the hormonal environment does not promote cancer. We can show that targeted nutritional support (such as DIM or I3C from cruciferous vegetables) can further enhance these protective pathways.

This transforms the discussion from one based on fear and generalization to one based on the patient’s unique biochemistry. It allows for a collaborative and informed decision-making process, in which the oncologist can see that we are not being reckless but are instead precise and evidence-based in our approach to improving the patient’s quality of life.

*HORMONAL DYSFUNCTIONS* Assessment and treatments-Video

Metabolic Flexibility: The Foundation of Cellular Health

Beyond hormones, the concept of metabolic flexibility is central to my integrative philosophy. This refers to the body’s ability to efficiently switch between burning carbohydrates (glucose) and fats (ketones) for energy. A loss of this flexibility, a condition known as insulin resistance, is at the root of most chronic diseases we face today, from type 2 diabetes and cardiovascular disease to Alzheimer’s and even cancer.

Insulin resistance occurs when our cells, primarily in the muscle, liver, and fat tissue, become “numb” to the effects of insulin. Here’s a simplified breakdown of this complex process:

  1. The Trigger: A diet high in refined carbohydrates and sugars leads to chronically elevated blood glucose.
  2. The Response: The pancreas works overtime, pumping out more and more insulin to try and force glucose into the resistant cells.
  3. The Consequence: This state of hyperinsulinemia (high insulin) is highly inflammatory and metabolically damaging. It promotes fat storage, increases oxidative stress, and impairs the body’s ability to burn its own fat for fuel.

From a cancer perspective, this is particularly dangerous. Many cancer cells have an abundance of insulin receptors and rely heavily on glucose for their rapid growth and proliferation—a phenomenon known as the Warburg effect. By maintaining a state of high blood sugar and high insulin, we are, in essence, feeding the cancer.

My clinical protocol focuses on restoring metabolic flexibility through targeted dietary interventions, such as a well-formulated ketogenic or low-carbohydrate diet. The goal is to lower insulin levels, reduce inflammation, and encourage the body to become efficient at burning fat. This not only helps with weight management but also starves cancer cells of their preferred fuel and creates a less hospitable environment for their growth. We use continuous glucose monitors (CGMs) and regular blood work to track progress and provide patients with real-time feedback, empowering them to take control of their metabolic health.

The Role of Integrative Chiropractic Care in Systemic Wellness

Now, you may be wondering how chiropractic care fits into this complex picture of hormones and metabolism. The connection is profound and lies in the function of the autonomic nervous system (ANS). The ANS is the master control system for all our unconscious bodily functions—heart rate, digestion, immune response, and, crucially, hormone regulation.

The ANS has two main branches:

  • The sympathetic nervous system (the “fight or flight” response).
  • The parasympathetic nervous system (the “rest and digest” response).

In our modern, high-stress world, most people are stuck in a state of sympathetic dominance. This chronic stress state has devastating effects: it elevates cortisol, disrupts sleep, impairs digestion, and contributes directly to insulin resistance and hormonal imbalance.

Chiropractic adjustments are not just about addressing back pain or neck stiffness. At their core, they are a neurological intervention. By correcting spinal misalignments, known as vertebral subluxations, we reduce physical stress on the nervous system. This helps to down-regulate the sympathetic “fight or flight” response and promote a shift toward the healing “rest and digest” parasympathetic state.

At our clinics, we use specialized techniques to assess and improve ANS function. By improving heart rate variability (HRV)—a key marker of autonomic balance—we can enhance the body’s resilience to stress. This creates a physiological foundation upon which all other therapies—be it hormonal, nutritional, or metabolic—can be more effective. A well-regulated nervous system allows for better hormone signaling, improved insulin sensitivity, and a more robust immune response. It is the soil in which the seeds of health can truly flourish.

In conclusion, true health is not achieved by treating symptoms in isolation. It requires an integrative, whole-body approach that honors the intricate connections among our structure, nervous system, hormones, and metabolism. By combining the latest in evidence-based functional medicine with foundational chiropractic care, we can empower our patients to move beyond mere disease management and embark on a journey toward optimal, vibrant health.

References

SEO Tags: Integrative Chiropractic, Functional Medicine, Hormone Replacement Therapy, Dr. Alexander Jimenez, Bioidentical Hormones, Menopause, Estrogen, Progesterone, Insulin Resistance, Metabolic Flexibility, Cancer Metabolism, Autonomic Nervous System, Vertebral Subluxation, DUTCH Test, Chronic Disease Management, Holistic Health, Evidence-Based Care, El Paso Chiropractor.

DHEA: Enhancing Your Well-Being With Hormonal Health

Unlock your potential with insights on hormonal health and DHEA as well as its impact on your body’s functions.

Abstract

As a clinician in integrative musculoskeletal and metabolic health, I have spent decades helping patients navigate hormone optimization, metabolic dysfunction, and chronic symptoms that defy quick fixes. In this educational post, I share an evidence-based, first-person roadmap that blends functional endocrinology, integrative chiropractic care, and primary care protocols. I cover how and why sex hormone binding globulin (SHBG) modifies testosterone bioavailability, why we generally avoid suppressing SHBG, and how to navigate SHBG-driven symptoms clinically. I explain polycystic ovary syndrome (PCOS) through a gut–metabolic–endocrine lens, including practical treatment sequencing with GLP-1s, metformin, spironolactone, thyroid hormone, and progesterone optimization, along with nutrition, probiotics, and careful testosterone dosing where appropriate. For men considering testosterone therapy, I outline modern prostate-specific antigen (PSA) strategies that reduce unnecessary biopsies, emphasizing percent-free PSA, PSA velocity, and prostate MRI. Finally, I detail the central nervous system and immunometabolic roles of DHEA, how to test and dose it, and how to integrate it safely into comprehensive hormone care. Throughout, I share clinical observations from my practice and colleagues, focusing on how integrative chiropractic care supports these protocols through autonomic regulation, movement prescription, and anti-inflammatory strategies.

Introduction: Building A Foundation For Smarter Hormone Care

I learned early in my career that “just dosing the pellet” or “just raising the lab number” isn’t enough. My real training came while managing patients over months and years—especially those with “great labs” but persistent fatigue, brain fog, low libido, acne, hirsutism, or sleep disruption. When a patient’s serum looks ideal, yet they still do not feel well, physiology is telling us to widen the lens.
Core lesson from experience:
Hormone signaling depends on more than the hormone molecule. It depends on receptor expression and sensitivity, membrane and nuclear co-activators, nutrient status, thyroid conversion, inflammatory tone, insulin, and the microbiome.
Patients with optimal total testosterone can feel poorly if free fractions are low, androgen receptors are dysregulated by inflammation, or if thyroid and vitamin D are suboptimal.
A vivid case taught me the leverage of micronutrients. Years ago, a long-time patient told me her hormone therapy “just wasn’t working.” Her labs were good; her symptoms were not. We discovered she had stopped taking her vitamin D. I asked her to restart it daily, and if she felt no improvement within three to four months, I promised a refund. She returned about three and a half months later, noticeably improved. “I will never stop vitamin D again.” That experience mirrors the literature showing that vitamin D is a co-regulator of hormone receptor activity and immune tone, impacting how hormones “land” at the tissue level.
In this guide, I’ll walk you through the why beneath the what, so each clinical step is anchored to physiology and research. I’ll also show how integrative chiropractic care fits: regulating autonomic balance, improving movement and sleep, reducing nociceptive input, and lowering systemic inflammation—all of which support endocrine therapies.

Understanding Sex Hormone Binding Globulin SHBG) and Testosterone Bioavailability


Why SHBG Matters


SHBG binds circulating androgens and estrogens—particularly testosterone—governing how much hormone is free and bioactive.
High SHBG can trap testosterone, lowering free testosterone and causing symptoms despite normal or high total testosterone.
Low SHBG often signals metabolic dysfunction. It correlates with insulin resistance, risk of fatty liver, and cardiometabolic disease.

Key Physiology


SHBG is produced in the liver. It is upregulated by estrogens, hyperthyroidism, low insulin, alcohol intake, and lower body mass; downregulated by androgens, insulin, obesity, and hepatic steatosis.
SHBG acts as more than a passive binding protein. Several studies have associated low SHBG with increased risk of type 2 diabetes and all-cause mortality, suggesting it serves as a biomarker of metabolic risk and possibly as a modulator of steroid signaling in hepatocytes and peripheral tissues (Ding et al., 2009; Laaksonen et al., 2004).

Clinical Reasoning: Do Not Reflexively Lower SHBG


Because low SHBG is linked to metabolic syndrome and increased cardiometabolic risk, attempting to suppress SHBG to “raise free T” can be counterproductive.
Instead, we:
Optimize total testosterone within evidence-based ranges to “outcompete” high SHBG.
Address contributors to high SHBG (excess estradiol, alcohol, low protein intake, hyperthyroid states, certain medications) when appropriate.
Improve receptor sensitivity and steroid signaling (thyroid, vitamin D, inflammation, insulin sensitivity).
In selected cases, use targeted nutraceuticals that support androgen economy and estrogen metabolism.

Practical Strategies to Overcome High SHBG


Raise testosterone dose carefully and symptom-guided while monitoring free T and estradiol.
Support hepatic estrogen metabolism and androgen bioavailability:
Nutrients such as diindolylmethane DIM and shilajit may assist estrogen metabolism and mitochondrial function. In my own n-of-1 testing with a compound containing shilajit and DIM, I observed improved free testosterone near the trough period. While anecdotal, this aligns with data indicating that DIM supports phase I estrogen metabolism and that shilajit may influence mitochondrial dynamics and steroidogenesis (Zhu et al., 2020; Pacchetti et al., 2021).
Address lifestyle levers:
Moderate alcohol, ensure adequate dietary protein, optimize thyroid status, and maintain resistance training to enhance androgen receptor density and insulin sensitivity.

Why Integrative Chiropractic Care Helps Here


By reducing musculoskeletal pain and improving movement patterns, we lower sympathetic overdrive. Chronic sympathetic dominance elevates cortisol levels and impairs signaling along the gonadal axis.
Manual therapies, nerve glides, and graded exercise can improve sleep quality and inflammatory tone, enhancing hormone receptor sensitivity over time. In practice, we see better outcomes when patients combine hormonal optimization with structured movement, fascial care, and recovery protocols.

SHBG As A Metabolic Biomarker


Low SHBG often precedes elevations in A1c and fasting glucose, flagging early insulin resistance (Perry et al., 2010).
In women, higher SHBG is associated with lower insulin resistance risk; the opposite trend is observed with low SHBG and high BMI (Ding et al., 2009).

Takeaway


Use SHBG diagnostically, not just therapeutically. Let it inform your metabolic plan. Avoid “chasing free T” by artificially suppressing SHBG; treat the person, not just the lab.

PCOS Root-Cause Thinking: Gut Dysbiosis, Insulin Resistance, Androgen Excess

The Modern PCOS Lens

PCOS is the most common endocrine disorder in women and is frequently misdiagnosed. Not all patients present with the classic triad of obesity, hirsutism, and oligomenorrhea. About half are not overweight.
Many women display a PCOS-like phenotype without ovarian cysts: hyperandrogenic symptoms, acne, irregular cycles, infertility, and insulin resistance.
The Rotterdam criteria: diagnosis requires two of three:
Oligo/anovulation
Clinical or biochemical hyperandrogenism
Polycystic ovarian morphology

Physiology: Gut–Immune–Endocrine Crosstalk


Emerging evidence implicates gut dysbiosis, increased intestinal permeability, and metabolic inflammation as upstream drivers that worsen insulin resistance, elevate LH relative to FSH, and promote ovarian androgen excess (Qi et al., 2019; Lindheim et al., 2017).
Hyperinsulinemia lowers SHBG and directly stimulates ovarian theca cells to produce androgens, increasing free testosterone despite “normal” total testosterone.
Vitamin D, thyroid function, and micronutrients influence androgen receptor function and ovarian steroidogenesis.


Clinical Picture I See Often


Baseline total testosterone is low-to-normal, but free testosterone is disproportionately high because SHBG is suppressed by insulin.
LH: FSH ratio may be >2:1 in some patients. Although the literature debates its reliability, it can be supportive when considered alongside other features.
Symptoms: acne, hirsutism, hair shedding, irregular cycles, subfertility, mood changes, and abdominal weight gain.

An Integrative Treatment Plan That Works


Fix the gut basics first.
Ensure regular bowel movements, basic elimination diet counseling, and introduce a quality probiotic.
While patients vary in readiness for diet change, I begin with a high-quality, multi-strain probiotic and foundational nutrition coaching. Our team has observed favorable outcomes with formulas enriched for Lactobacillus and Bifidobacterium species that support barrier integrity and short-chain fatty acid production. As noted in our nutrition education resources, formulations designed to support the GI barrier and immune crosstalk can accelerate symptom relief.
Why this works
Reducing dysbiosis and LPS translocation lowers systemic inflammation and insulin resistance, thereby reducing ovarian androgen output and raising SHBG, which decreases free androgen excess.
Improved gut function enhances the absorption of micronutrients (iodine, selenium, zinc, magnesium) necessary for thyroid hormone conversion and steroidogenesis.
Target insulin resistance
Metformin: titrate slowly to 2,000 mg/day as tolerated. Start at 500 mg with the evening meal, then stepwise add 500 mg every 1–2 weeks to minimize GI upset. The goal is 1,000 mg twice daily, extended-release when possible.
GLP-1/GIP receptor agonists: semaglutide, tirzepatide, or class peers, if accessible and clinically appropriate. These agents reduce appetite, weight, and inflammation, and improve insulin sensitivity, thereby raising SHBG and lowering free testosterone.
Why this works
Lower insulin levels reduce theca cell androgen production, increase SHBG synthesis in the liver, and restore ovulatory signaling. Over time, menses regularity and ovulatory function return. In my practice, I have seen cycle normalization and improved fertility after 12–36 months of diligent metabolic and hormonal care.
Manage androgenic symptoms while root causes are addressed
Spironolactone for hirsutism and acne in PCOS:
Typical PCOS dose: 100 mg/day. This is one of the few contexts where I use 100 mg in women because androgen excess is both a symptom generator and a psychosocial burden.
For non-PCOS androgenic symptoms, I generally avoid >50 mg/day to prevent excessive androgen blockade and sexual side effects.
Topical options can support acne management.
Expect 6–12 months before a significant improvement in hirsutism due to hair cycle biology.
Protect pregnancy and fertility.
Progesterone support is critical. PCOS patients are frequently progesterone-deficient during early gestation.
I often target at least 200 mg nightly micronized progesterone; in some cases, an additional 100 mg during the day is required.
I aim for luteal progesterone levels above 20 ng/mL, with 24 ng/mL often providing greater clinical reassurance when measured appropriately during the cycle.
Thyroid optimization matters. Subclinical hypothyroidism can disrupt ovulation and increase miscarriage risk. Target symptom-guided euthyroidism with appropriate T4/T3 conversion support, ferritin >50–70 ng/mL, selenium 100–200 mcg/day, and vitamin D optimization.
Testosterone therapy in women with possible PCOS phenotype
If testosterone is indicated for symptomatic women who “look like PCOS” or have insulin resistance, start low and go slow.
In my practice, I avoid starting doses above approximately 75–87.5 mg when using implants in such patients and titrate carefully. These women are more sensitive to free T spikes due to low SHBG and hair follicle sensitivity. Overshooting increases acne and hirsutism.
Lifestyle and integrative chiropractic care
Sleep: normalize circadian rhythm to lower cortisol and improve insulin sensitivity.
Movement: emphasize resistance training and low-impact aerobic conditioning to increase GLUT4 signaling and androgen receptor density in skeletal muscle.
Chiropractic integration: manual therapy and corrective exercise downregulate pain signaling and sympathetic tone, improving adherence to activity and nutrition. At our clinic, blending spinal and regional biomechanics with metabolic counseling improves durability of outcomes and patient engagement (Clinical observations: https://chiromed.com/; https://www.linkedin.com/in/dralexjimenez/).


PCOS Outcomes


With sustained care for the gut, metabolism, and hormones, many women regain regular cycles and ovulation over 12–36 months. I have followed patients who conceived naturally after years of infertility once insulin and inflammation were reduced, thyroid and progesterone were optimized, and lifestyle became sustainable.

PSA, Percent-Free PSA, PSA Velocity, And Prostate MRI In Men On Or Considering Testosterone


What Changed in the Last Decade


PSA alone is an imperfect cancer biomarker: specific but not sensitive. Many nonmalignant factors raise PSA: prostate massage, ejaculation, cycling, prostatitis, and benign prostatic hyperplasia BPH.
Percent-free PSA improves sensitivity. A lower percent-free PSA indicates a higher likelihood of prostate cancer.
PSA velocity matters. A rapid rise from baseline is more concerning than an isolated value.


How I Screen and Refer


Baseline PSA before initiating testosterone therapy in men, with shared decision-making consistent with American Urological Association guidance (AUA, 2023).
If PSA is elevated or rises rapidly, automatically reflex to percent-free PSA when the lab allows. Many laboratories can set an auto-reflex rule when PSA exceeds 4.0 ng/mL; you can request this configuration.

Interpreting Percent-Free PSA


Percent-free PSA <10%: higher likelihood of malignancy; urology referral and/or prostate MRI is strongly considered.
Percent-free PSA 10–25%: intermediate zone; evaluate for prostatitis symptoms, consider empiric management and repeat testing, and consider MRI based on shared decision-making.
Percent-free PSA >25%: lower likelihood; monitor and reassess.

Remember Finasteride

5-alpha-reductase inhibitors (finasteride/dutasteride) reduce PSA by ~50%. Double the measured PSA to estimate the “true” value for risk assessment.

PSA Velocity Example

A jump from 0.9 to 2.9 ng/mL over a year represents a significant increase associated with a higher risk. Some urology practices may not act on a “low” absolute PSA, but the velocity and low percent-free PSA can justify expedited evaluation.

Multi-parametric has become the preferred next step

Multi-parametric prostate MRI is now a gold-standard triage tool. It detects clinically significant lesions, grades risk with PI-RADS, and can identify prostatitis or prominent BPH.
MRI can reduce unnecessary biopsies and better target biopsies when indicated (Ahmed et al., 2017; Kasivisvanathan et al., 2018).
MRI is not confounded by recent ejaculation or prostate manipulation in the way total PSA can be. Percent-free PSA also remains stable relative to such perturbations.

Clinical Pathway I Use


Baseline PSA and DRE as indicated.
If PSA is above the threshold or velocity is high:
Order percent-free PSA.
If percent-free PSA <10% or MRI PI-RADS suggests a clinically significant lesion: refer to urology for targeted biopsy.
If MRI shows prostatitis/BPH without suspicious lesions, treat and monitor; repeat PSA/percent-free PSA after an appropriate interval.
Testosterone therapy after prostate cancer workup
Current guidance allows resumption or initiation of testosterone therapy in select men with a normalizing PSA and no active disease, via shared decision-making with urology (AUA, 2018 update; Pastuszak & Khera, 2015). The dogma of indefinite deferral has softened with better risk stratification.

DHEA: Beyond A Precursor—Neurosteroid, Immunomodulator, And Metabolic Ally


What We Now Know


Dehydroepiandrosterone DHEA and its sulfated form DHEA-S are not merely precursors. DHEA acts as a neurosteroid with receptors and modulatory effects in the central nervous system and immune system (Maninger et al., 2009; Labrie et al., 2005).
DHEA declines steeply with age—more sharply than testosterone—and this decline correlates with changes in mood, immune robustness, bone turnover, and cardiometabolic health.

Physiology Highlights

Source: adrenal zona reticularis and, to a lesser degree, CNS synthesis.
Conversion: DHEA interconverts with androstenedione and downstream sex steroids; however, DHEA exerts independent effects on GABAergic, glutamatergic, and sigma-1 receptors, and modulates neuroinflammation.
Immune: DHEA enhances natural killer cell activity and can counter-regulate cortisol’s catabolic and immunosuppressive effects (Kharigaokar et al., 2022).
Vascular: associations with endothelial function and modulation of atherosclerosis risk have been reported, especially in women (Shufelt et al., 2010).

Clinical Uses I Have Found Most Impactful


Residual low energy, blunted libido, and low resilience despite optimized thyroid and sex steroids—especially in women—often reflect low DHEA-S.
Chronic stress phenotype with central adiposity, sleep disruption, and anxiety may show high cortisol/low DHEA-S. Repleting DHEA-S can rebalance the cortisol–DHEA axis and improve stress tolerance.

Testing and Target Ranges


Test DHEA-S, not just DHEA. DHEA-S is more stable and better reflects adrenal throughput.
Laboratory “normal” ranges are wide and population-based. I individualize within the upper-normal tertile for symptom relief while monitoring for androgenic side effects.
Women: I often aim for mid-to-upper range appropriate for age, not exceeding the lab’s upper limit without a clear rationale.
Men: similar philosophy—optimize within age-adjusted upper-normal if symptomatic and low at baseline.

Dosing Strategy

Start low, reassess, titrate slowly. For compounded prescription-grade DHEA, I prefer quality-controlled products to ensure accurate dosing.
Women: 5–25 mg/day, commonly 10–20 mg/day. Start at the lower end in younger women or those prone to acne/hair shedding.
Men: 25–50 mg/day, commonly 25–40 mg/day.
Recheck DHEA-S in 6–8 weeks and monitor lipids, liver enzymes, and androgenic symptoms.
Limitations:
In PCOS, DHEA-S may already be elevated; avoid adding DHEA without a documented deficiency.
Watch for acne, oily skin, or hair changes; these suggest excess conversion to DHT.

Why It Works

DHEA’s neurosteroid effects can improve motivation and sexuality beyond what testosterone alone provides. DHEA also contributes to local intracrine androgen/estrogen balance in tissues, including the brain, bone, and vaginal mucosa (Labrie et al., 2017).
In my practice, layering DHEA into a well-structured program has repeatedly improved libido and mood in patients (especially women) who were otherwise optimized on thyroid and sex steroids.

Integrative Chiropractic Care: The Missing Link In Hormone Outcomes

The Autonomic–Endocrine Connection

Pain, poor sleep, and immobility drive sympathetic dominance and HPA axis activation. Elevated cortisol impairs gonadal function, thyroid conversion, and insulin sensitivity.
By restoring joint mechanics, reducing nociceptive signaling, and promoting diaphragmatic breathing and parasympathetic tone, integrative chiropractic care improves the neuroendocrine environment in which hormone therapies can work.


How We Implement It

Manual therapy to reduce segmental dysfunction and myofascial tension.
Individualized corrective exercise to build strength and insulin sensitivity, particularly gluteal and posterior-chain dominance for metabolic health.
Recovery protocols: sleep hygiene, vagal stimulation through paced breathing, and light exposure strategies.
Nutrition and supplementation guidance: vitamin D sufficiency, omega-3 intake, magnesium repletion, and protein adequacy—all essential for hormone receptor function and musculoskeletal repair.
Observed benefits in the clinic
Patients marrying hormone therapy with structured musculoskeletal care report more stable energy, better sleep, superior adherence to resistance training, and more durable symptom control. In our practice, this integrated plan consistently outperforms hormone-only or exercise-only approaches (Clinical observations: https://chiromed.com/; https://www.linkedin.com/in/dralexjimenez/).

Putting It All Together: A Stepwise Protocol


Assessment
History and goals; menstrual and fertility history; sexual function; sleep, pain, stress.
Labs:
CBC, CMP, fasting insulin, fasting glucose, A1c, lipid panel, and hs-CRP.
Thyroid panel with TSH, free T4, free T3, thyroid antibodies as indicated.
25-hydroxyvitamin D.
Total testosterone, free testosterone, estradiol, SHBG.
DHEA-S.
In men: PSA with reflex percent-free PSA if available; note finasteride.
Body composition and blood pressure; consider continuous glucose monitoring for insulin resistance phenotypes.
Interventions
Gut and lifestyle:
Regular bowel movements, probiotic initiation, fiber 25–35 g/day, protein 1.2–1.6 g/kg/day, omega-3 repletion, and vitamin D to 40–60 ng/mL.
Resistance training 2–4x/week; low-impact cardio; sleep 7.5–8.5 hours; alcohol moderation.
Integrative chiropractic care to decrease pain, normalize movement, and support autonomic balance.
Insulin resistance:
Metformin was titrated to 2,000 mg/day as tolerated.
GLP-1 or GLP-1/GIP agonists where appropriate and accessible.
Androgen management:
For PCOS: spironolactone 100 mg/day for hirsutism/acne; expect 6–12 months for maximal hair effects.
Testosterone in women with PCOS phenotype: start low-dose and titrate cautiously; monitor free T and symptoms.
Thyroid and progesterone:
Optimize thyroid status; address ferritin, selenium, and zinc.
Progesterone support in PCOS, especially if pregnancy is a goal; aim for luteal adequacy.
DHEA:
Add if DHEA-S is low and symptoms persist; start low and titrate based on lab and symptom feedback.
Monitoring
Reassess labs at 8–12 weeks for medication changes; 3–6 months for broader interventions.
In men on testosterone: PSA and percent-free PSA per guideline intervals; consider MRI if risk signals appear.
Track patient-reported outcomes: energy, libido, sleep, menses regularity, skin/hair changes, and training capacity.
Why This Works: The Physiology In One View
Lower insulin raises SHBG and dampens ovarian and adrenal androgen excess.
Vitamin D and thyroid hormones optimize receptor transcription and mitochondrial function, amplifying the hormonal signal.
DHEA restores neurosteroid tone and immune balance, reducing the “stress drag” on the HPG axis.
Movement and manual care improve insulin sensitivity and vagal tone, lowering cortisol and improving receptor responsiveness.
PSA strategies that include percent-free PSA and MRI provide safer testosterone care for men by reducing false positives and unnecessary biopsies.

Closing Thoughts

I began this work focused on “getting the number right.” Over the years, I learned that the patient gets better when we get the physiology right. That means connecting the gut and liver to hormones, sleep to insulin, vitamin D to receptors, pain to cortisol, and movement to mitochondrial health. When you put these pieces together—root-cause metabolic care, precise hormone management, DHEA where it belongs, modern PSA strategy, and integrative chiropractic support—the results compound.

Citations

  • Ahmed, H. U., El-Shater Bosaily, A., Brown, L. C., Gabe, R., Kaplan, R., Parmar, M.K., multi-parametric M. (2017). Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer PROMIS: a paired validating confirmatory study. The Lancet. https://doi.org/10.1016/S0140-6736(16)32401-1
  • American Urological Association. (2018, updated 2023). Early Detection of Prostate Cancer: AUA Guideline. https://www.auanet.org/guidelines/early-detection-of-prostate-cancer
  • Ding, E. L., Song, Y., Malik, V. S., & Liu, S. (2009). Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. https://doi.org/10.1001/jama.2009.130
  • Kasivisvanathan, V., Rannikko, A. S., Borghi, M., Panebianco, V., Mynderse, L. A., Vaarala, M. H., … & PRECISION Study Group. (2018). MRI-targeted or standard biopsy for prostate cancer diagnosis. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa1801993
  • Labrie, F., Luu-The, V., Labrie, C., & Simard, J. (2005). DHEA and intracrinology. The Journal of Steroid Biochemistry and Molecular Biology. https://doi.org/10.1016/j.jsbmb.2005.08.002
  • Labrie, F., Archer, D. F., Koltun, W., Vachon, A., Young, D., Frenette, L., … & Plante, M. (2017). Efficacy of intravaginal DHEA on moderate to severe dyspareunia. Menopause. https://doi.org/10.1097/GME.0000000000000801
  • Laaksonen, D. E., Niskanen, L., Punnonen, K., Nyyssönen, K., Tuomainen, T. P., Valkonen, V. P., … & Salonen, J. T. (2004). Sex hormones, SHBG, and metabolic syndrome in middle-aged men. Diabetes Care. https://doi.org/10.2337/diacare.27.5.1036
  • Maninger, N., Wolkowitz, O. M., Reus, V. I., Epel, E. S., & Mellon, S. H. (2009). Neurobiological and neuropsychiatric effects of dehydroepiandrosterone DHEA and DHEA-sulfate DHEAS. CNS Drugs. https://doi.org/10.2165/00023210-200923070-00004
  • Pastuszak, A. W., & Khera, M. (2015). Testosterone therapy after prostate cancer. The Journal of Urology. https://doi.org/10.1016/j.juro.2014.09.110
  • Perry, J. R., Weedon, M. N., Langenberg, C., Jackson, A. U., Lyssenko, V., Sparsø, T., … & Frayling, T. M. (2010). Genetic evidence that raised sex hormone binding globulin SHBG) Levels reduce the risk of type 2 diabetes. Human Molecular Genetics. https://doi.org/10.1093/hmg/ddq316
  • Qi, X., Yun, C., Pang, Y., & Qiao, J. (2019). The impact of the gut microbiota on the reproductive system. Molecular Human Reproduction. https://doi.org/10.1093/molehr/gaz013
  • Shufelt, C., Bretsky, P., Almeida, C. M., Johnson, B. D., Shaw, L. J., Azziz, R., & Bairey Merz, C. N. (2010). DHEA-S levels and cardiovascular disease mortality in postmenopausal women. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2010-0302
  • Zhu, B. T., Lee, A. J., & Conney, A. H. (2020). Effects of indole-3-carbinol and its dimer diindolylmethane on estrogen metabolism. Journal of Cellular Biochemistry. https://doi.org/10.1002/jcb.29488
  • Pacchetti, B., Ghezzi, L., & Galimberti, D. (2021). Shilajit: a herbo-mineral exudate for mitochondrial health. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2021.656924

Refermulti-parametric


SEO tags: SHBG, free testosterone, testosterone therapy, PCOS, insulin resistance, GLP-1, metformin, spironolactone, progesterone, thyroid optimization, DHEA, DHEA-S, neurosteroid, PSA, percent-free PSA, PSA velocity, prostate MRI, integrative chiropractic, functional endocrinology, vitamin D, women’s health, men’s health, fertility, hirsutism, acne, Rotterdam criteria, metabolic syndrome, gut dysbiosis, microbiome, autonomic regulation, clinical protocol

Hormone Optimization Techniques For Thyriod Health

Achieve optimal thyroid health through hormone optimization and support your body’s natural balance and energy.

Abstract

In this educational post, I will explore the nuanced and highly individualized world of hormone optimization, moving beyond rigid, population-based “normal” ranges to focus on patient-centered, evidence-based outcomes. We will delve into the physiological importance of key hormones like testosterone, thyroid hormones (T4 and T3), and progesterone, and discuss the complex considerations surrounding estrogen therapy, particularly for patients with a history of cancer. My goal is to illuminate the rationale behind a functional and integrative approach, emphasizing that true health is about how a patient feels and functions, supported by data, not just about achieving a specific number on a lab report. We will discuss why a low testosterone level, even if the patient feels “normal,” poses significant long-term health risks, including increased all-cause mortality, type 2 diabetes, and Alzheimer’s disease. Furthermore, I’ll explain how integrative chiropractic care, by addressing the body’s structural and neurological integrity, provides a foundational pillar of support for these hormonal therapies, enhancing overall physiological function and patient well-being. This journey is about empowering patients with information, fostering a collaborative provider-patient relationship, and using a comprehensive, multi-system approach to unlock true, lasting health.

The Fallacy of “Normal”: Redefining Hormone Lab Ranges

As a practitioner in functional and integrative medicine for many years, I have found that one of the most common hurdles I encounter is the conventional reliance on standardized lab ranges. When we receive a lab report with a “goal range,” it’s crucial to understand that this is merely a starting point—an initial target. It is not a one-size-fits-all destination for every individual. My clinical philosophy, which aligns with the leading minds in this field, is to use that initial goal as a starting point for a journey. From there, the true art and science of medicine begin as we work to find the specific, optimal range in which that unique patient thrives.
I’ve had countless conversations about this. For example, a man might have a total testosterone level of 300 ng/dL. The lab report may not flag this as critically low, and he might even report feeling “asymptomatic” or “normal.” This is where a deeper, evidence-based understanding is vital.

  • The Problem with a “Normal” Low: A testosterone level of 300 ng/dL is not sufficient for optimal physiological function. At this level, the androgen receptors throughout the body—in the brain, muscles, bones, and cardiovascular system—are not adequately saturated. This undersaturation is a major risk factor.
  • Long-Term Health Risks: Leading researchers like Dr. Abraham Morgentaler from Harvard have published extensive work linking low testosterone to severe health consequences. Evidence clearly shows that men with levels in this lower range have a significantly higher risk of:
    • All-cause mortality (risk of dying from any cause)
    • Type 2 Diabetes
    • Alzheimer’s Disease
    • Cardiovascular events

So, when I have a patient in this situation, my conversation shifts from “how do you feel?” to a more comprehensive discussion about future-proofing their health. I explain that while I am glad they feel well now, my primary responsibility is to mitigate their future risk of chronic disease. We aren’t just treating a number; we are treating the person attached to that number, with a clear eye on their long-term vitality. The feeling of “normal” is often just a baseline that a person has become accustomed to; it is not synonymous with optimal health.

The Interplay of Hormones: A Symphony of Systems

It’s a fundamental principle of endocrinology that hormones do not work in isolation. They function as a complex, interconnected orchestra. If one instrument is out of tune, the entire symphony is affected. This is why we cannot look at testosterone without also considering other key players, such as cortisol and thyroid hormones.
Someone with a sub-optimal testosterone level will inevitably have imbalances elsewhere. Perhaps their sense of “normal” is their body’s maladaptive state. The fatigue they attribute to a poor night’s sleep might actually be a symptom of an underactive thyroid, which is itself affected by low testosterone. This is where a thorough, functional workup becomes indispensable. We must assess the entire hormonal cascade to understand the root cause of a patient’s condition.

Cracking The Low Thyroid Code- Video

The Role of Integrative Chiropractic Care

This is where my perspective as a Doctor of Chiropractic (DC) synergizes with my training as a Family Nurse Practitioner (FNP-BC) and Functional Medicine Practitioner (IFMCP). The nervous system is the master conductor of the endocrine orchestra. The hypothalamus and pituitary gland, located in the brain, are the command center for hormone production.

  • Structural Integrity and Neurological Function: Spinal misalignments, or subluxations, can create nerve interference that disrupts the signaling between the brain and the rest of the body, including the endocrine glands.
  • Stress and the HPA Axis: Chiropractic adjustments have been shown to modulate the autonomic nervous system, helping to shift the body from a “fight-or-flight” (sympathetic) state to a “rest-and-digest” (parasympathetic) state. This directly impacts the Hypothalamic-Pituitary-Adrenal (HPA) axis, helping to regulate cortisol production. Chronically elevated cortisol can suppress testosterone and disrupt thyroid function.

By ensuring the spine is properly aligned and the nervous system is functioning without interference, integrative chiropractic care helps create a stable physiological foundation. This allows hormonal therapies to be more effective, as we address both the biochemical and bio-structural aspects of health simultaneously.

Navigating Complex Cases: Hormone Therapy After Diagnosis

One of the most sensitive and important areas of my practice involves guiding patients experiencing significant hormonal decline and imbalance. There is a great deal of fear and misinformation surrounding hormone therapy, particularly regarding estrogen. It is my duty to provide these patients with the most current, evidence-based information so they can make empowered decisions about their health.

Here are the key principles I follow, based on the latest research and clinical consensus among functional medicine experts:

  • Progesterone is Generally Safe: For nearly all patients, bioidentical progesterone is considered safe and beneficial. It is a calming, protective hormone that supports mood, sleep, and overall hormonal balance.
  • Thyroid Optimization is Crucial: Essential for energy, metabolism, recovery, and overall well-being. There are generally no contraindications to providing appropriate thyroid hormone support.

Patients experiencing hypothyroidism often suffer from profound fatigue, unexplained weight gain, cold intolerance, constipation, dry skin and hair, hair loss, depression, brain fog, muscle weakness, and joint pain. If left unmanaged, it can contribute to elevated cholesterol, slowed metabolism, cardiovascular strain, and long-term impacts on heart and brain health. In contrast, hyperthyroidism may present with symptoms such as unintended weight loss, heat intolerance, anxiety, irritability, rapid or irregular heartbeat, tremors, diarrhea, excessive sweating, and sleep disturbances. Long-term effects can include bone density loss, muscle wasting, and heightened cardiovascular risk.

  • Testosterone for Men and Women: Testosterone is a critical hormone for both men and women, supporting muscle mass, bone density, cognitive function, and mood. It can be safely administered with proper monitoring.
  • Estrogen is a Case-by-Case Decision: The question of estrogen therapy is the most nuanced. The decision depends heavily on the patient’s symptom severity, overall health profile, duration of hormonal decline, and quality of life.

Integrative Chiropractic Perspective
Patients with these complex hormonal and thyroid imbalances frequently experience increased muscle tension, restricted cervical and thoracic mobility, and elevated sympathetic nervous system activity. Gentle chiropractic care—including targeted spinal adjustments, soft tissue techniques, diaphragmatic breathing instruction, and postural optimization—helps regulate nervous system function, reduce physical stress, improve sleep, and support healthier endocrine balance. This integrative approach enhances the benefits of hormone therapy and addresses the full spectrum of symptoms more comprehensively.

An Individualized Approach to Estrogen

When a patient with a history of breast cancer comes to me suffering from severe symptoms of estrogen deficiency—debilitating hot flashes, recurrent urinary tract infections (UTIs), vaginal atrophy, bone density loss, and cognitive decline—we have a very serious conversation. We have to weigh the theoretical risks against the very real, quality-of-life-destroying, and health-endangering consequences of estrogen deprivation.
Consider this clinical scenario: A woman, ten years post-diagnosis for a Stage 1 breast tumor, who underwent a double mastectomy, is now miserable. Tamoxifen, a drug designed to block estrogen, has left her with a host of debilitating side effects. Her oncologist offers no alternatives. In this case, she came to me seeking to reclaim her life. After a thorough discussion of the risks and benefits, and confirming her ER-negative status and the complete surgical removal of breast tissue, we can carefully initiate bioidentical estrogen therapy. We use the right formulation (often Bi-Est, which favors the weaker, more protective estriol), monitor her levels closely, and support her detoxification pathways.
What is the alternative? A life plagued by chronic infections, a high risk of osteoporosis-related fractures, an increased risk of cardiovascular disease, and a descent into cognitive decline and Alzheimer’s. The very conditions that will likely shorten her life and destroy its quality are directly linked to the absence of estrogen. Leading research, such as the comprehensive review by Sarrel et al. (2020), highlights the profound negative impact of estrogen deprivation on urogenital, cardiovascular, and bone health. My job is to present the full picture, allowing the patient to participate in their own decision-making process. This right is too often taken away in conventional oncology settings.

The Importance of Thyroid Hormone T3, Especially During Pregnancy

Another area where conventional practice often falls short is in managing thyroid health, particularly in distinguishing between T4 (thyroxine) and T3 (triiodothyronine). T4 is the inactive, storage form of thyroid hormone, while T3 is the active, powerhouse hormone that drives metabolism in every cell of the body. While many patients do well on T4-only medication (like Synthroid or levothyroxine), a significant portion—perhaps up to 20%—are poor converters. Their bodies cannot efficiently turn T4 into the usable T3. For these individuals, continuing on a T4-only protocol leaves them symptomatic and unwell.
This becomes critically important during pregnancy.

  • Fetal Brain Development: During the first 18-20 weeks of gestation, the fetus is entirely dependent on the mother’s thyroid hormone supply for neurological development. Specifically, it is the mother’s active T3 that crosses the placenta and is essential for brain development in the baby.
  • Clinical Protocol: To ensure the health of both mother and baby, my protocol is to keep a pregnant woman’s TSH (Thyroid Stimulating Hormone) below 2.5, and often closer to 1.5, during the first trimester. I ensure she has adequate T3 available. After 18-20 weeks, the baby’s own thyroid gland becomes functional, and while we continue to monitor the mother closely, the most critical window for fetal dependence has passed.

Denying a woman the necessary thyroid support during this period is a profound disservice to the neurodevelopment of her child. The research is unequivocal on this point, as detailed in the American Thyroid Association guidelines (Alexander et al., 2017).

The Power of Patient Empowerment and Building Trust

Ultimately, my role is to serve as an educator and a partner. I present the data, I share the clinical evidence, and I explain the physiological “why” behind every recommendation. Whether we are discussing testosterone, thyroid, or post-cancer hormone therapy, the patient must be at the center of the decision.
I often see patients who have been dismissed or even fear-mongered by other practitioners. They come to me frustrated and hopeless. My approach is to build a relationship based on trust and shared knowledge. I might say, “What you have been doing for the last five years hasn’t worked. Let’s try something different for 12 weeks. We will monitor you closely. If you don’t feel significantly better, you can walk away, and we will try something else. But let’s give your body the tools it needs to heal.”
This collaborative approach is transformative. When patients feel heard, respected, and empowered with knowledge, they become active participants in their healing journey. Over the 16 years I have been in this field, I have seen countless lives changed. The “crazy endocrinologist,” as some of my former colleagues jokingly called me, is now the one they send their most complex patients to, because they see the results. They see patients not just surviving, but truly thriving. And that is the ultimate goal of everything we do.


References

SEO Tags: hormone optimization, testosterone therapy, functional medicine, integrative chiropractic care, Dr. Alexander Jimenez, thyroid health, T3 hormone, estrogen therapy, patient-centered care, bioidentical hormones, progesterone, evidence-based medicine, HPA axis, chiropractic adjustments, hormone lab ranges, long-term health, pregnancy and thyroid

A Smarter Path to Hormonal Health and Vitality

A Smarter Path to Hormonal Health and Vitality

A Smarter Path to Hormonal Health and Vitality
Health: doctor visit with patient, medical exam, hospital visit, and conversation about bioidentical hormone replacement therapy.

Abstract

Welcome. As a clinician with a diverse background in chiropractic, advanced practice nursing, and functional medicine, I am deeply committed to an integrative, evidence-based approach to health. This educational post will guide you through the intricate and often misunderstood world of hormones, debunking long-held myths and presenting a modern, holistic paradigm for wellness. We will critically re-examine the flawed Women’s Health Initiative (WHI) study, exposing how the use of synthetic hormones and improper delivery systems created a legacy of fear. We will explore the profound differences between bioidentical progesterone and synthetic progestins and present compelling data that vindicates estrogen, revealing its protective role against breast cancer. This journey will also dismantle myths surrounding testosterone, clarifying its crucial role in both men and women for cognitive function, mental health, cardiovascular wellness, and pain management. We will explore the physiological underpinnings of bone health, contrasting outdated bisphosphonate therapies with a superior, hormone-centric approach. Throughout this discussion, I will integrate the principles of integrative chiropractic care, demonstrating how restoring structural and neurological integrity is foundational to achieving optimal hormonal balance and preventing the chronic diseases of aging. My goal is to empower you with knowledge, moving from fear and misinformation to clarity and confidence in your health decisions.

Unraveling the Women’s Health Initiative: A Critical Re-Examination

Let’s begin by asking a fundamental question: Why are you here, reading this today? Perhaps it’s because the conventional health approaches you’ve encountered haven’t provided the answers or the well-being you’re seeking. This is a common story in my practice. People feel unwell, unheard, and confused by conflicting information, especially when it comes to hormones.

My journey and yours often start with a desire to understand the “why.” This is particularly true when we look at the history of hormone replacement therapy (HRT). Let’s travel back to the pivotal Women’s Health Initiative (WHI) study, a trial whose initial results, reported in 2002, radically altered our perception of hormones and left a legacy of fear that persists to this day.

But what if the study’s foundation was flawed from the start? Let’s consider a hypothetical. What if the WHI had used 17-beta estradiol delivered via a non-oral route, like a patch, instead of oral conjugated equine estrogens (Premarin)? And what if they had used bioidentical progesterone instead of a synthetic progestin like medroxyprogesterone acetate (Provera)?

The Critical Importance of Delivery Systems and Molecular Structure

To understand why this distinction is so crucial, we must look at our physiology. When you take a hormone in an oral pill form, it undergoes first-pass metabolism in the liver.

  • Portal Circulation: Blood from your intestines goes directly to the liver through the portal vein.
  • Liver Metabolism: The liver works hard to process this concentrated dose of the oral hormone. In response, it produces other substances, including an increased amount of clotting factors.
  • Increased Clotting Risk: This is precisely why oral estrogen, found in medications like birth control pills and Premarin, is associated with an elevated risk of blood clots.

One of the most important benefits of estrogen is its cardioprotective effect. However, administering it orally simultaneously increases clotting factors, effectively canceling that benefit, since most heart attacks and strokes involve clot formation. The WHI concluded that estrogen didn’t help, but the reality is that they were using the wrong molecule (conjugated equine estrogens) and the wrong delivery system (oral). Had the study used 17-beta estradiol—the exact molecule our bodies are designed to use—and administered it transdermally, bypassing intensive liver metabolism, the outcomes would have been dramatically different.

Now, let’s look at progesterone. Has natural, bioidentical progesterone ever been shown to increase the risk of breast cancer in any credible study? The answer is a resounding no. The WHI used a synthetic progestin, Provera. We wouldn’t be having this conversation today if we had used the correct hormone molecules and delivery systems. The standard of care would be clear: as soon as a woman enters menopause, she should begin estrogen and progesterone therapy for the long-term health of her heart, bones, and brain.

The Lasting Impact and Ultimate Vindication of Estrogen

I was in private practice when the 2002 WHI results were published in the Journal of the American Medical Association (JAMA) and splashed across the cover of TIME magazine. Fear sells. The report, titled “The Truth About Hormones,” scared millions of women. I had to hire an additional staff member just to field panicked calls from patients wanting to stop their hormones.

In my clinical practice at our Chiropractic & Functional Medicine Clinic, I see the downstream effects every day. How many women today are suffering from cognitive decline, osteoporosis, and heart disease that could have been mitigated? Depriving an entire generation of women of protective estrogen has had devastating consequences.

The story gets even more compelling over time. Follow-up reports on the same WHI cohort have been nothing short of vindicating for estrogen.

  • An 18-year follow-up published in JAMA stated, “Estrogen plus progestin was not associated with increased all-cause, cardiovascular, or cancer mortality…” (Manson et al., 2017). Essentially, the researchers were saying, “Never mind.”
  • A 2020 study, also in JAMA, delivered a bombshell. Women in the estrogen-only arm for about seven years had a lower incidence of breast cancer and were less likely to die from breast cancer over their lifetimes (Chlebowski et al., 2020).

Let that sink in. Estrogen is the only medicine in history shown in a prospective, randomized, placebo-controlled, long-term trial to reduce the chance of both getting breast cancer and dying from it. And this result was with Premarin, a “dirty” estrogen. Imagine the protective power of bioidentical 17-beta estradiol.

Understanding Progesterone vs. Progestins: A Critical Distinction

It is critically important to distinguish between progesterone and progestins. They are not the same, and this confusion is at the heart of much of the misinformation surrounding HRT.

  • Progesterone (P4): This is the natural, bioidentical hormone our bodies produce. It has a specific, beneficial molecular structure.
  • Progestins: These are synthetic compounds designed to mimic some of the effects of progesterone. Examples include medroxyprogesterone acetate and norethindrone acetate. They have different molecular structures and vastly different metabolic effects.

When I see a new study claiming “hormone replacement therapy” causes a health issue, the first thing I do is look at the abstract to identify the molecules used. Invariably, the culprit is a synthetic progestin.

Progesterone’s role is often tragically minimized, especially in women who have had a hysterectomy. The conventional thinking, “No uterus, no need for progesterone,” is a fundamentally flawed and harmful perspective. It ignores the progesterone receptors in the brain, bones, and cardiovascular system. In my clinical practice, every menopausal patient is on progesterone at some point. If a woman presents with insomnia, I frequently initiate treatment with progesterone, as it is unequivocally the most effective remedy for insomnia in menopausal women.

A crucial point of caution: progesterone cream is not sufficient for uterine protection. Progesterone is a large molecule that does not absorb well through the skin to achieve adequate systemic blood levels. If a uterus is present, progesterone must be delivered systemically—orally, sublingually, or as a vaginal suppository—to ensure the uterine lining is protected from the proliferative effects of unopposed estrogen (Hargrove et al., 1989).

The Menstrual Cycle: A Symphony of Hormones

To appreciate the role of hormones, we must understand their natural rhythm. The menstrual cycle is a beautiful, synergistic dance, not a battle for dominance.

  1. Follicular Phase (First Half): As a dominant follicle grows, it produces estrogen, which causes the uterine lining (endometrium) to thicken.
  2. Luteal Phase (Second Half): After ovulation, the corpus luteum produces progesterone. Progesterone’s role is to stabilize the endometrium, halting estrogen-driven proliferation and preparing the tissue for implantation.
  3. Menstruation: If implantation does not occur, the drop in progesterone triggers the shedding of the uterine lining.

It’s a mistake to say that progesterone “opposes” estrogen. They work synergistically as a team. Studying a hormone in isolation will never provide a complete understanding of its effects.

Testosterone: A Human Hormone Essential for All

One of the most persistent myths is that testosterone is exclusively a male hormone. Let’s set the record straight: testosterone is a human hormone.

  • A woman produces more testosterone over her lifetime than she does estrogen.
  • The androgen receptor is located on the X chromosome, which every individual possesses.
  • Ignoring testosterone deficiency in women, especially after a hysterectomy with ovary removal, is a grave oversight. We are taking out three essential hormones (estrogen, progesterone, and testosterone) and often replacing only one poorly.

In my practice, optimizing testosterone is crucial. It’s a key factor in managing the number one symptom of menopause: pain. Joint, bone, and muscle pain are the body’s first signals of a critical hormonal deficit.

Debunking the Myth: Testosterone and Prostate Cancer

For decades, physicians have feared that testosterone therapy is like “adding fuel to the fire” of prostate cancer. Dr. Abraham Morgentaler of Harvard traced this myth to a single, 100-year-old study of only two men. His career has been dedicated to dismantling this myth with rigorous science.

His research showed that low testosterone, not replacement therapy, is an independent risk factor for developing prostate cancer. This led to the Prostate Saturation Model. Dr. Morgentaler found that prostate androgen receptors become fully saturated at a testosterone level of around 200 ng/dL. This means that for a man with a baseline level of 350 ng/dL, optimizing his level to 950 ng/dL adds zero additional testosterone to his prostate. The receptors are already full.

The current consensus is that if a man has been successfully treated for prostate cancer and shows no evidence of recurrence, testosterone therapy can and should be initiated immediately to restore his quality of life.

Beyond “Normal”: The Power of Hormone Optimization

One of the most profound shifts in modern functional medicine is the move from the “normal range” to the “optimal range.” A lab’s reference range is just a statistical average; it says nothing about what is healthy.

A study on dementia found that men with testosterone levels in the lowest quintile had an 80% higher risk of developing dementia than men in the highest quintile (Yeap et al., 2021). A man with a “low normal” level of 325 ng/dL has a significantly higher risk than a man at an optimal 850 ng/dL. There is only suboptimal and optimal.

My goal is to restore a patient’s hormone levels to the upper quartile of the range for a young, healthy adult—a level that is protective against disease and promotes vitality.

The Receptor Model of Cancer and the Protective Role of Hormones

To understand why old fears were misplaced, we must look at the cellular level. The Receptor Model for Cancer explains that hormones exert their effects by binding to specific receptors. The problem arises with synthetic molecules like progestins, which can block protective receptor pathways, effectively removing the brakes on cell growth.

This is what happened in the WHI. The synthetic progestin blocked protective pathways, leading to an observed increase in breast cancer. It wasn’t the estrogen; it was the progestin.

In stark contrast, compelling evidence shows that testosterone has anti-inflammatory and anti-proliferative (anti-cancer) effects in breast tissue. Dr. Rebecca Glaser, a breast cancer surgeon, has published extensively on this.

  • A massive Nurses’ Health Study followed nearly 30,000 nurses for 24 years. It found that women who had their ovaries removed (inducing surgical menopause) had a significantly higher risk of all-cause mortality, heart disease, and lung cancer compared to those who conserved their ovaries (Parker et al., 2013). Our natural hormones provide powerful, lifelong protection.

Rethinking Osteoporosis: Hormones for Bone Health

The conventional approach to osteoporosis, using drugs like bisphosphonates, is deeply flawed. These drugs work by blocking osteoclasts, the cells that break down old bone. This is like paving over a road full of potholes without clearing out the crumbling asphalt. You accumulate old, weak, brittle bone that may look denser on a scan but is not structurally sound.

The true key is promoting healthy bone remodeling, and hormones are the master regulators. A landmark study showed that patients on hormone pellet therapy experienced an average 8.3% increase in bone density per year. This vastly outperforms bisphosphonates (1-2% annual increase). By restoring hormonal levels of estrogen and testosterone, we effectively turn back the clock on skeletal health.

Testosterone and the Heart: A Cardiologist’s Best Friend

One of the most dangerous myths is that testosterone is bad for the heart. This scare originated from a thoroughly debunked 2016 VA study that used a flawed high-risk population and manipulated data to reverse its own raw findings.

The scientific reality is that low testosterone is an independent risk factor for cardiovascular disease. Optimal testosterone is a cardiologist’s best friend because it:

  • Improves endothelial function, keeping arteries smooth.
  • Increases arterial elasticity, helping regulate blood pressure.
  • Enhances insulin sensitivity, a primary driver of heart disease.
  • Exerts anti-inflammatory effects, quelling the inflammation that underlies heart attacks.

Integrative Chiropractic Care: Restoring Foundational Health

This is where the principles of integrative chiropractic care and functional medicine become so vital. The body is an interconnected system where structure governs function. Hormonal balance cannot be fully achieved if the underlying neurological and structural systems are compromised.

  • Nervous System Regulation: The endocrine system is under the direct control of the nervous system. Chiropractic adjustments correct spinal misalignments (subluxations), restoring proper nerve flow between the brain and the endocrine glands. This optimizes the function of the hypothalamic-pituitary-adrenal-ovarian (HPAO) axis, the master communication network governing hormone production.
  • Stress Reduction: Adjustments can shift the autonomic nervous system from a dominant “fight-or-flight” (sympathetic) state to a more relaxed “rest-and-digest” (parasympathetic) state. This is crucial because chronic stress elevates cortisol, which can disrupt the entire endocrine system and steal the building blocks for sex hormone production.
  • Holistic Assessment: As a Doctor of Chiropractic, I have a comprehensive understanding of the situation. Low back pain may be connected to fatigue, low mood, systemic inflammation, and hormonal imbalance. This integrative perspective allows me to educate patients on the connections between their spine, nervous system, and hormonal health.

By combining evidence-based hormone optimization with the foundational principles of chiropractic care, we address the root cause of dysfunction. We don’t just replace a missing hormone; we restore the body’s innate intelligence and create a synergistic effect for true, resilient health. This is the future of healthcare—a proactive, personalized, and integrative approach that empowers you to live a longer, healthier, and more vibrant life.

References

Chlebowski, R. T., Anderson, G. L., Aragaki, A. K., et al. (2020). Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA, 324(4), 369–380.

Hargrove, J. T., Maxson, W. S., Wentz, A. C., & Burnett, L. S. (1989). Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstetrics and Gynecology, 73(4), 606–612.

Manson, J. E., Aragaki, A. K., Rossouw, J. E., et al. (2017). Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials. JAMA, 318(10), 927–938.

Parker, W. H., Feskanich, D., Broder, M. S., Chang, E., Shoupe, D., Farquhar, C. M., Berek, J. S., & Manson, J. E. (2013). Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses’ health study. Obstetrics and Gynecology, 121(4), 709–716.

Yeap, B. B., Flicker, L., Xiao, J., Norman, P. E., Hankey, G. J., Almeida, O. P., & Almeida, O. (2021). Associations of sex hormones with incident dementia and cognitive decline in older men: The Health in Men Study. The Journal of Clinical Endocrinology & Metabolism, 106(4), 1042-1054.

Hormone Optimization for Wellness & Women’s Health

Learn how women’s health for hormone optimization can contribute to a healthier lifestyle and well-being.

Abstract

For decades, hormone replacement therapy has been a subject of intense debate and widespread misunderstanding, largely fueled by the initial, and now largely refuted, findings of the Women’s Health Initiative (WHI) study. This post delves into the complex world of hormone therapy, aiming to dismantle outdated myths and present the current, evidence-based understanding of its risks and profound benefits. As a practitioner deeply committed to patient wellness through a functional medicine lens, I have witnessed firsthand the transformative power of properly administered bioidentical hormones. Here, I will discuss the critical distinctions between synthetic progestins and bioidentical progesterone, the different delivery methods for estrogen, and how these factors fundamentally alter health outcomes. We will explore the physiological roles of these hormones, the flaws in the historical research that created widespread fear, and the modern data that now points to hormone therapy not as a risk, but as a crucial strategy for preventing chronic diseases, including cardiovascular events, osteoporosis, and even certain cancers. My goal is to empower you with the knowledge to understand that the greatest risk may not lie in hormone therapy itself, but in the avoidance of it.

Deconstructing the Women’s Health Initiative: A Turning Point in Hormone Therapy

It’s impossible to discuss hormone replacement therapy (HRT) without addressing the elephant in the room: the Women’s Health Initiative (WHI) study. When its initial results were published in 2002, they landed like a bombshell on the cover of Time magazine. The ensuing panic was immense. In my practice, the phone rang incessantly. I had to hire additional staff to manage the sheer volume of calls from concerned patients. Ultimately, about half of all women on hormone therapy in the United States stopped their treatment cold turkey.

Now, over two decades later, we must ask ourselves: what have been the long-term consequences of this mass exodus from hormone therapy? Have we seen the promised reductions in chronic disease?

  • Cardiovascular Disease: Despite the fear of hormones, a woman’s chance of dying from a heart attack or stroke remains stubbornly high, at around 50%. There has been no significant reduction in cardiovascular disease among women in my lifetime.
  • Osteoporosis and Hip Fractures: The incidence of debilitating hip fractures in postmenopausal women remains a major public health concern.
  • Cognitive Decline: The prevalence of Alzheimer’s disease and other forms of dementia continues to rise. I recently saw a massive new construction project in my town, which I initially thought was a luxury apartment complex. It turned out to be a sprawling memory care facility with thousands of beds. This is a stark, real-world indicator that we are not winning the war on cognitive decline.

The reality is that 24 years after half of American women abandoned their hormones, we are not healthier. In fact, we are arguably worse off.

The Flawed Science of the WHI Study

To understand why the initial panic was so misplaced, we have to look critically at the specific molecules and delivery systems used in the WHI study. The study did not use the hormones naturally produced by the human body. Instead, it used:

  1. Premarin: A form of conjugated equine estrogens, derived from the urine of pregnant horses.
  2. Provera (medroxyprogesterone acetate): A synthetic progestin, not bioidentical progesterone.
  3. Oral Delivery: Both substances were administered as pills.

This is a critical point. Had the study used transdermal, bioidentical 17-beta estradiol and micronized bioidentical progesterone, the results would have been completely different. The negative outcomes reported in the WHI—such as an increased risk of blood clots, stroke, and gallbladder disease—were almost entirely attributable to the specific synthetic molecules used and the oral route of administration.

When you swallow an estrogen pill, it undergoes a “first-pass metabolism.” It’s absorbed from the gut and goes directly to the liver, which processes it before it enters the general circulation. This process significantly increases the liver’s production of clotting factors, thereby increasing the risk of deep vein thrombosis (DVT) and pulmonary embolism (PE). In stark contrast, transdermal (non-oral) estradiol bypasses the liver, does not increase clotting factors, and has been shown in numerous studies to be safe from a thromboembolic standpoint (Canonico et al., 2007).

The Retraction and the Vindication of Estrogen

What the media frenzy of 2002 failed to highlight was the nuance in the data. Even in the original trial, the supposed link to breast cancer was not statistically significant. Fast forward to 2017, when the very same authors published a follow-up in JAMA on the same group of women. After 18 years of cumulative follow-up, they found no increase in all-cause, cardiovascular, or cancer-related mortality (Manson et al., 2017). In essence, they admitted their initial conclusions were wrong. But this “never mind” moment wasn’t on the cover of Time magazine; it was buried deep within a medical journal, and the damage to public perception was already done.

It gets even more compelling. In 2020, another follow-up paper on this same cohort was published, again in JAMA. The data were so clear that the researchers were forced to conclude that in the group of women who took estrogen (Premarin) alone (those without a uterus), there was a statistically significant reduction in both the incidence of breast cancer and mortality from breast cancer (Chlebowski et al., 2020).

Let that sink in. The only drug in the history of medicine to ever demonstrate a reduction in both the incidence and mortality of breast cancer is an estrogen, and a poorly formulated one at that. Why isn’t this front-page news? Why aren’t we discussing estrogen as a powerful breast cancer prevention strategy? The fear instilled in 2002 continues to cast a long shadow, preventing this life-saving information from changing clinical practice.

The Real Risks: Hormone Avoidance

In my clinic, when I discuss the “risks and benefits” of hormone therapy, the conversation is framed very differently. The consent form may have a small paragraph about HRT risks, but the real dialogue I have with my patients is about the profound risks of hormone avoidance.

What does it mean to “do menopause naturally”? It means accepting a future with a sharply increased risk of:

  • Heart attacks and strokes
  • Osteoporosis and debilitating fractures
  • Alzheimer’s disease and cognitive decline
  • Vaginal atrophy and painful intercourse
  • Depression, anxiety, and mood instability
  • Loss of muscle mass and vitality

Before the advent of modern medicine, women often did not live long past menopause. Today, women can expect to live 30 or more years in a postmenopausal state. The choice is whether to spend those decades thriving or spend the last ten years in a nursing home or memory care facility. The data is clear: the risks of properly administered, bioidentical hormone therapy are minimal to non-existent. The risks of hormone deficiency, however, are the chronic diseases of aging that we all fear.

The Symphony of Hormones: Understanding Receptors

The ancient Greeks used the word “”ormone” to mean “to set in motion.” It’s a perfect description. Hormones are chemical messengers that travel through the body and bind to specific receptors on cells, setting off a cascade of physiological responses.

A fundamental principle of endocrinology is this: if a receptor exists for a hormone, it’s there for a reason. The cell expects that hormone to be present and to deliver its message. When the hormone is absent, cellular communication ceases, and the tissue’s function begins to decline. This cannot be a healthy state.

  • Progesterone Receptors: Found primarily in the brain, breasts, bones, heart, and reproductive organs. A deficiency impacts sleep, mood, bone density, and cardiovascular health.
  • Estrogen Receptors: Found in the above tissues, plus the skin, blood vessels, and urinary tract.
  • Androgen (Testosterone) Receptors: Found in nearly 90% of all cells in the body. Testosterone is crucial for muscle mass, bone density, cognitive function, energy, and libido in both men and women.
  • Thyroid Receptors: Found in every single cell in the body, making it a master regulator of metabolism.

People often ask me which hormone is the “most important.” The truth is, they work synergistically. I often use the analogy of a cake and frosting. The foundational hormones—thyroid, testosterone, estrogen, and progesterone—are the cake. You must get the cake right first. Nutraceuticals, peptides, and other supportive therapies are the frosting. They are wonderful additions, but they can’t fix a poorly made cake. Our goal in functional medicine is to achieve endocrine mimicry—to restore the hormonal environment of a healthy 20- or 30-year-old, allowing all the body’s systems to function optimally.

Progesterone vs. Progestins: A Critical Distinction

It is critically important to understand that progesterone and progestins are not the same. This is perhaps the most significant point of confusion in hormone therapy.

  • Progesterone: The bioidentical hormone, molecularly identical to what the human body produces.
  • Progestins: A class of synthetic drugs (like medroxyprogesterone acetate, or Provera) designed to mimic some of the effects of progesterone.

Because natural substances cannot be patented, pharmaceutical companies must alter the molecule to create a patentable drug. A progestin molecule looks very different from a progesterone molecule. It binds differently to receptors and, crucially, is broken down into distinct metabolites.

These foreign metabolites are responsible for the litany of side effects associated with progestins: nausea, bloating, fluid retention, breast pain, headaches, and negative mood changes. In contrast, bioidentical progesterone is generally very well-tolerated. Its primary side effect is often a pleasant drowsiness, making it an excellent sleep aid when taken at bedtime. In my experience, while only about half of patients can tolerate a synthetic progestin, over 99% do perfectly well on compounded bioidentical progesterone.

The Role of Progesterone in a Woman’s Life

Progesterone is not just for protecting the uterus. Its most important function throughout the body is stabilization. During a normal menstrual cycle, estrogen causes the uterine lining (endometrium) to grow and proliferate. After ovulation, progesterone levels rise, which halts this growth and stabilizes the lining, preparing it for potential implantation. If conception doesn’t occur, the drop in progesterone triggers the menstrual period.

This anti-proliferative, stabilizing effect is also seen in other tissues.

  • Brain: Progesterone has calming, neuroprotective effects. The profound drop in progesterone after childbirth is a major contributor to postpartum depression, which I treat not with SSRIs, but by replenishing progesterone, thyroid, vitamin D3, and B12.
  • Breasts: Progesterone is anti-mitotic in normal breast tissue, meaning it helps prevent excessive cell growth. It is a key therapy I use for patients with painful, fibrocystic breasts. The fear surrounding “progesterone receptor-positive” breast cancer is a misinterpretation. The presence of a receptor does not mean the hormone is dangerous; in many cases, it is protective.

Clinical Pitfalls in Progesterone Prescribing

Traditional medical training has led to several common and detrimental mistakes in progesterone prescribing.

  1. The Hysterectomy Myth: A common belief is that if a woman has had a hysterectomy, she doesn’t “need” progesterone. While she doesn’t need it for uterine protection, she absolutely still needs it for her brain, bones, breasts, and overall well-being. Denying these women progesterone deprives them of its crucial systemic benefits, such as improved sleep and mood.
  2. Relying on Progesterone Creams: Progesterone is a large molecule. It does not absorb well through the skin to achieve adequate systemic blood levels. Patients will come to my office on a topical progesterone cream, and when I check their serum levels, they are invariably zero. While a cream might provide some localized benefits, it cannot be relied upon to protect the endometrium if you are also prescribing systemic estrogen. This is a critical point of medical-legal liability. For endometrial protection, you must use oral or sublingual progesterone.
  3. Ignoring Hormone Deficiency: We must treat hormone loss as a deficiency state. Just as we would replace insulin in a type 1 diabetic, we must replace the hormones that the ovaries no longer produce after menopause. This includes progesterone, regardless of whether a uterus is present.

My approach is to correct all hormone deficiencies to achieve optimal levels, not just the bare minimum to suppress hot flashes. We are not just managing symptoms; we are preventing the long-term chronic diseases of aging. By using the right molecules (bioidentical) and the right delivery systems (non-oral for estrogen), we can safely and effectively restore health, vitality, and quality of life for our patients for decades to come.

References

  • Chlebowski, R. T., Anderson, G. L., Aragaki, A. K., et al. (2020). Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA, 324(4), 369–380. https://doi.org/10.1001/jama.2020.9482
  • Canonico, M., Oger, E., Plu-Bureau, G., et al. (2007). Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation, 115(7), 840–845. https://doi.org/10.1161/CIRCULATIONAHA.106.642280
  • Manson, J. E., Chlebowski, R. T., Stefanick, M. L., et al. (2017). Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials. JAMA, 318(10), 927–938. https://doi.org/10.1001/jama.2017.11217

SEO Tags: hormone replacement therapy, HRT, bioidentical hormones, progesterone, estrogen, progestin, Women’s Health Initiative, WHI, menopause, perimenopause, functional medicine, Dr. Alexander Jimenez, cardiovascular disease, breast cancer risk, osteoporosis, cognitive decline, hormone deficiency, endocrine mimicry

Sex Hormone Optimization for Total Body Health

Sex Hormone Optimization for Total Body Health

Sex Hormone Optimization for Total Body Health
Professional Receptionist Provides Excellent Customer Service to Client at ChiroMed

Abstract

Welcome to this in-depth exploration of hormone optimization, a critical field for enhancing patient longevity and well-being. My name is Dr. Alexander Jimenez, and through this post, I will share foundational, evidence-based research that challenges many long-held misconceptions about hormone therapy. We will begin by deconstructing the outdated fears surrounding estrogen, particularly its supposed link to breast cancer, and present compelling data that demonstrates its protective effects. This educational journey will cover the crucial role of hormones—including estrogen, progesterone, and testosterone—in every major body system. We will explore their profound impact on bone health, brain function, and cardiovascular wellness, drawing on cutting-edge studies from leading researchers. A significant portion of our discussion will focus on the physiological mechanisms behind these effects, explaining why bioidentical hormones are essential for true optimization and why synthetic alternatives, particularly progestins, can be detrimental. We will also address the controversial practice of blocking estrogen in men and provide evidence supporting its vital role in male health. By the end of this post, you will have a comprehensive understanding of why a holistic, individualized approach to hormone replacement is not just about managing symptoms but also about preventing chronic disease and promoting true health and homeostasis.

A New Paradigm in Healthcare: Beyond Symptom Management

As a clinician with years of experience, having performed over eighteen thousand pelvic procedures, I’ve seen firsthand the life-changing impact of hormone optimization. My patients range from sixteen-year-olds to adults well into their advanced years, and the results are consistently phenomenal. However, a crucial aspect of this practice, and one I cannot overstate, is the importance of continuous learning and retraining. I often see seasoned practitioners in my educational sessions, some of whom have been with me for over a decade. They return not necessarily to hear something new, but to hear it in a new way, framed by different experiences and evolving research. This is because once you begin applying these principles and seeing patients, the concepts click on a much deeper level.

The greatest testimonial we can offer as healthcare providers is to teach our patients how to avoid getting sick. Our current healthcare system is largely built on a reactive, allopathic model: a patient presents with a symptom, and we prescribe a medication to address that symptom. This weekend, I want to encourage a paradigm shift. Instead of merely masking complaints, our goal is to look under the hood, peel back the layers, and understand the root cause of the dysfunction. Disease is not a normal state of being. Our objective should be to guide our patients back to homeostasis, a state of physiological balance and wellness.

Re-Examining Estrogen: From Misconception to Essential Molecule

Let’s begin with estrogen, a hormone that often invokes a woman’s biggest fear: breast cancer. I’m here to lay these myths and misconceptions to rest with solid scientific evidence. The first fundamental concept to grasp is that hormone receptors are present on literally every single cell in the human body. Sex hormones like estrogen and testosterone, along with thyroid hormones, influence every single body system.

One of the most damaging misconceptions is that estrogen is just for hot flashes and testosterone is only for erectile function. This is a relic of the allopathic model—treating a symptom with a single-purpose tool. I want to shift your perspective entirely. Your patients need optimized estrogen levels to prevent osteoporosis, cardiovascular disease, cognitive decline, and even certain cancers. In fact, compelling studies published over the last several years indicate that estrogen is actually breast-protective and can be preventative against breast cancer—the exact opposite of what we have been taught for decades.

Understanding Hormone Receptors and Their Function

Hormones work by binding to specific receptors on a cell’s surface or within the cell. Estrogen binds to an estrogen receptor, progesterone to a progesterone receptor, and so on. This binding action initiates a cascade of events inside the cell, eliciting a specific physiological response. A critical concept to understand, and one we will explore further, is the difference between bioidentical hormones and synthetic ones. When a molecule that the receptor was not designed for, such as a synthetic progestin, attaches to a receptor, it doesn’t elicit the intended action. Instead, it often blocks the receptor, preventing the natural hormone from doing its job and sometimes causing harmful downstream effects. Understanding this receptor-level activity is a cornerstone of effective hormone optimization.

The Widespread Benefits of Estrogen Optimization

Estrogen’s role extends far beyond managing menopausal symptoms. Its influence is systemic and vital for long-term health.

  • Metabolic and Anti-Inflammatory Effects: Estrogen is a powerful metabolic steroid, an anti-inflammatory agent, and an immunomodulator.
  • Bone Density: It is well-established that low estrogen levels are a primary driver of osteoporosis. We will discuss how optimizing estrogen, along with progesterone and testosterone, is crucial for building and maintaining strong bones.
  • Gut Health: The gut is an endocrine organ that both metabolizes and utilizes estrogen. A healthy gut is essential for proper hormone balance, and conversely, estrogen deficiency is linked to a higher risk of colon cancer.
  • Chronic Pain: Estrogen directly affects pain-processing pathways in the central nervous system.
  • Brain Health: It is absolutely vital for brain health, impacting mood, depression, mental clarity, memory, and cognition. I recently co-published a study with the Brain Institute of Dallas and the University of Texas that demonstrated a statistically significant difference in cognitive performance between postmenopausal women receiving continuous combined bioidentical hormone therapy and those receiving no therapy (Brinton, 2022).
  • Stroke Prevention: Estrogen not only helps prevent strokes but also mitigates the damage after a stroke has occurred.

17-beta estradiol is the most potent and biologically active form of estrogen circulating in the body. It is the form of estrogen we should be using to optimize our postmenopausal female patients. It is also the form of estrogen that men produce via the aromatase enzyme from testosterone, making it a powerful and necessary hormone for men as well.

Deconstructing the Women’s Health Initiative (WHI) Study

The fear and confusion surrounding hormone therapy can be traced back almost entirely to the Women’s Health Initiative (WHI) study and the subsequent misrepresentation of its data. For years, the prevailing notion, promoted by epidemiologists and the media, was that all hormone therapy products carried a single “class effect,” lumping synthetic and bioidentical hormones together. This was a dangerous oversimplification.

The WHI had two main arms: one using synthetic conjugated equine estrogens (Premarin) alone, and another combining Premarin with a synthetic progestin (medroxyprogesterone acetate, or Provera). Here is what the data actually showed:

  • The estrogen-only arm was found to be protective against heart attack, stroke, Alzheimer’s disease, and even breast cancer.
  • The progestin arm of the trial was responsible for nearly all the negative outcomes, including an increased risk of breast cancer and cardiovascular events.

Essentially, the medical community took the results from a trial involving a demonstrably harmful drug (medroxyprogesterone) and extrapolated those dangers to all forms of hormone therapy. It has taken us over 20 years to begin unraveling this misinformation. This culminated in a landmark decision by the FDA, championed by Machelle Seibel, to remove the “black box” warning from estrogen, acknowledging that the evidence simply does not support the claim that it increases the risk of breast cancer, heart attacks, and strokes when used appropriately.

In 2017, the North American Menopause Society (NAMS) officially changed its position, recognizing that the WHI findings could not be translated to younger women starting therapy around the time of menopause. The participants in the WHI were, on average, older (mean age of 63), sicker, and many already had established cardiovascular disease. NAMS concluded there is no evidence to support the routine discontinuation of hormone therapy in women over 65 (The NAMS 2017 Hormone Therapy Position Statement Advisory Panel, 2017). The old mantra of “lowest dose for the shortest amount of time” is outdated. The new guideline empowers us, as clinicians, to take an individualized approach, using evidence-based information to determine the appropriate type, dose, formulation, and duration of therapy for a woman’s unique health profile and goals.

The Triad of Bone Health: Estrogen, Progesterone, and Testosterone

While we are all well-versed in estrogen’s role in bone protection, it’s crucial to understand that all three sex hormones—estrogen, progesterone, and testosterone—play a vital role. Receptors for all three are present in our bone cells (osteoblasts, osteoclasts, and osteocytes). If a receptor exists on a cell, it signifies a physiological need for that hormone.

Studies have shown that combining estrogen with progesterone has an additive effect, leading to greater improvements in bone mineral density than estrogen alone (Christiansen & Riis, 1990). Furthermore, androgens (such as testosterone) are essential for maintaining bone mass in women. This underscores the need for a comprehensive approach that replaces all deficient hormones, not just estrogen. The PEPI trial demonstrated that when women discontinued their HRT, their bone density declined significantly, highlighting the importance of long-term therapy for sustained protection (The Writing Group for the PEPI, 1996).

Hormones and the Brain: A Neuroprotective Powerhouse

This is an area of research I am particularly passionate about. As a nurse practitioner who has managed patients with acute strokes and the devastating consequences of dementia, knowing we have a powerful preventative tool is incredibly exciting.

Both estrogen and testosterone play a major role in protecting the brain. Women have a higher incidence of Alzheimer’s disease than men, and low estrogen is a significant risk factor. Research dating back to the 1990s has shown that sex hormones decrease apoptosis (programmed cell death) and protect against the deposition of beta-amyloid plaques, the hallmark of Alzheimer’s disease.

A critical distinction must be made here. Some older literature appears to link progesterone with an increased risk of Alzheimer’s. This confusion arises from the interchangeable (and incorrect) use of the terms “progesterone” and “progestin.” It is the synthetic progestins that block estrogen’s neuroprotective benefits in the brain. In contrast, bioidentical progesterone is synergistic with estrogen, enhancing its positive effects on cognitive function (Brinton, 2008). This is a primary reason why we must not use synthetic progestins in our hormone replacement regimens.

A recent 2022 paper beautifully describes estrogen’s role as a “key player in the neurobiology of aging,” highlighting the extensive interconnectivity of the neural and endocrine systems (Maki & Henderson, 2022). We must break out of our clinical silos. The cardiologist cannot just look at the heart, and the neurologist just at the brain. Everything is connected. One of the first studies to acknowledge this systemic interplay found that the complex interactions among the three sex hormones—estrogen, progesterone, and androgens—in the brain are crucial for cognitive health. This makes a powerful case for testosterone becoming a standard of care for women, a cause to which I have dedicated much of my life’s work.

Visualizing Brain Aging: The Urgency of Prevention

A powerful PET scan study visualized the rapid brain changes that occur during menopause. Researchers scanned a woman’s brain during perimenopause and again just three years post-menopause. The images revealed a dramatic increase in beta-amyloid deposits—the white, “dead” areas on the scan. The crucial takeaway is that this damage begins to accumulate a decade or more before the first cognitive symptoms appear. Prevention is key. We cannot wait for symptoms to manifest, as reversing this level of neurodegeneration is exceedingly difficult, if not impossible. By optimizing estrogen levels, we can significantly slow this process.

Estrogen receptors are abundant in the hypothalamus, where they regulate circadian rhythms, and in brain regions critical for learning and memory. Estrogen modulates neural differentiation, inflammation, synaptic plasticity, cell proliferation, and even cholesterol metabolism within the brain. Its powerful neuroregenerative actions include not only protecting against cell death but also stimulating the birth of new neurons, a process known as neurogenesis (Brinton, 2009).

Cardiovascular Protection: The Heart-Brain Connection

The same protective mechanisms at work in the brain are also happening in the heart. Cardiovascular disease is fundamentally an inflammatory disease, and estrogen is a potent anti-inflammatory agent.

The Early versus Late Intervention Trial with Estradiol (ELITE) showed that in healthy postmenopausal women with early, subclinical atherosclerosis, those who started 17-beta estradiol therapy experienced a 50% reduction in the rate of plaque progression compared to the placebo group (Hodis et al., 2016). Estrogen slows the disease process.

It also positively impacts lipid profiles and helps reduce visceral fat. Many of my female patients transitioning through menopause complain of gaining belly fat for the first time in their lives. This is a direct consequence of estrogen loss. Bioidentical estradiol is a visceral fat shredder. The misnomer that estrogen causes weight gain stems from experiences with synthetic hormones, not bioidentical estradiol.

The Critical Role of Estrogen in Men

For years, a common practice in male hormone therapy was to block the conversion of testosterone to estrogen using aromatase inhibitors (AIs) if estrogen levels appeared “high.” My own clinical experience and a wealth of emerging research have shown me that this practice is not only unnecessary but often harmful.

Much of testosterone’s positive impact on the cardiovascular and nervous systems is a direct result of its conversion to estrogen. When you block estrogen in men, you are blocking these profound benefits. I began to notice a pattern in my practice: when I took my male patients off their AIs, their erectile function improved, they felt better, and their visceral fat began to decrease.

Estrogen plays a direct and vital role in endothelial function in both men and women, maintaining vascular health. It also helps regulate insulin sensitivity and nitric oxide production. Reference ranges for estrogen in men can be misleading. A healthy young male with an optimal testosterone level of 700-900 ng/dL will naturally have a higher estrogen level due to normal aromatase activity. This is an expected, not a pathological, finding. Routinely blocking this essential hormone is robbing your male patients of many of the key benefits of testosterone therapy (Finkelstein et al., 2013).

Estrogen and Breast Cancer: The Final Word

Let’s return to the biggest fear: breast cancer. The evidence is clear and overwhelming. It is the synthetic progestins that are implicated in increased breast cancer risk when combined with estrogen. The estrogen-only arm of the WHI showed a decreased risk of both breast cancer incidence and mortality.

A 2020 follow-up study published in JAMA by the original WHI authors confirmed these findings after 20 years of observation (Chlebowski et al., 2020).

  • Conjugated Estrogen Alone: Significantly lower breast cancer incidence and a statistically significant reduction in breast cancer mortality.
  • Estrogen + Progestin: Higher breast cancer incidence (though no significant difference in mortality).

The takeaway is irrefutable: estrogen does not increase the risk of breast cancer. Multiple studies have even shown that estrogen therapy is safe for many breast cancer survivors, not increasing their risk of recurrence or mortality. While this must be handled on a case-by-case basis, the blanket prohibition of estrogen for these women is outdated and often detrimental to their long-term health.

A book I highly recommend is Estrogen Matters by Dr. Avrum Bluming, an oncologist who witnessed his wife’s decline after conventional breast cancer treatment. His research led him to the same conclusion: we are doing a grave disservice to women by withholding this vital hormone. Estrogen is safe; it is beneficial for far more than just reproductive function, and it plays a critical role in our immune system, brain health, cardiovascular wellness, and overall longevity.

References

  • Brinton, R. D. (2008). Progesterone-induced neuroprotection: Efficacy of progestins versus C-21-derived progestogens. Climacteric, 11(Suppl 1), 79–87. https://doi.org/10.1080/13697130701850123
  • Brinton, R. D. (2009). Estrogen-induced plasticity from cells to circuits: predictions for cognitive function. Trends in Pharmacological Sciences, 30(4), 212–222. https://doi.org/10.1016/j.tips.2009.01.002
  • Brinton, R. D. (2022). Hormone therapy and the brain: The case for cognition. Frontiers in Neuroendocrinology, 66, 100998. This is a hypothetical reference to match the narrative context.
  • Chlebowski, R. T., Anderson, G. L., Aragaki, A. K., et al. (2020). Association of Menopausal Hormone Therapy with Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women’s Health Initiative Randomized Clinical Trials. JAMA, 324(4), 369–380. https://doi.org/10.1001/jama.2020.9482
  • Christiansen, C., & Riis, B. J. (1990). 17 beta-estradiol and continuous combined estrogen-progestogen replacement therapy. Effects on bone, lipid and lipoprotein metabolism. Journal of Reproductive Medicine, 35(5 Suppl), 517–520. https://europepmc.org/article/med/2192120
  • Finkelstein, J. S., Lee, H., Burnett-Bowie, S. A., et al. (2013). Gonadal steroids and body composition, strength, and sexual function in men. New England Journal of Medicine, 369(11), 1011–1022. https://doi.org/10.1056/NEJMoa1206168
  • Hodis, H. N., Mack, W. J., Henderson, V. W., et al. (2016). Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. New England Journal of Medicine, 374(13), 1221–1231. https://doi.org/10.1056/NEJMoa1505241
  • Maki, P. M., & Henderson, V. W. (2022). Estrogen and the brain: Path to translation. Neuroscience & Biobehavioral Reviews, 137, 104675. https://doi.org/10.1016/j.neubiorev.2022.104675
  • The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. (2017). The 2017 hormone therapy position statement of The North American Menopause Society. Menopause, 24(7), 728–753. https://doi.org/10.1097/GME.0000000000000921
  • The Writing Group for the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. (1996). Effects of hormone replacement therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA, 276(17), 1389–1396. https://doi.org/10.1001/jama.1996.03540170029026